Illumina Inc
NASDAQ:ILMN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
92.072
155.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Illumina Inc
Net Margin
Illumina Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | US |
| Market Cap | 22.3B USD |
| Net Margin |
-36%
|
| Country | US |
| Market Cap | 1.3T USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 196.3B USD |
| Net Margin |
14%
|
| Country | US |
| Market Cap | 170.3B USD |
| Net Margin |
18%
|
| Country | KR |
| Market Cap | 66.5T KRW |
| Net Margin |
24%
|
| Country | CH |
| Market Cap | 37.6B CHF |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 38.5B USD |
| Net Margin |
22%
|
| Country | US |
| Market Cap | 36.7B USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 26.4B USD |
| Net Margin |
21%
|
| Country | US |
| Market Cap | 23B USD |
| Net Margin |
17%
|
| Country | US |
| Market Cap | 22.2B USD |
| Net Margin |
21%
|
Illumina Inc
Glance View
Illumina Inc. is a pioneering biotechnology company that has revolutionized the field of genomics by developing advanced sequencing technologies that unveil the secrets of the human genome. Founded in 1998 and based in San Diego, California, Illumina has positioned itself at the forefront of genetic research, providing scientists and clinicians with tools that enhance disease detection, treatment options, and personalized medicine. With a commitment to innovation, Illumina’s sequencers have made genetic sequencing faster, cheaper, and more accessible—empowering researchers to explore the genetic underpinnings of health and disease like never before. Their flagship products, such as the NovaSeq and NextSeq series, are instrumental in various applications, from cancer research and reproductive health to infectious disease surveillance. For investors, Illumina represents a unique opportunity in the rapidly expanding biotechnology sector. The company’s robust growth trajectory is underpinned by strategic partnerships with leading research institutions and pharmaceutical companies, fostering a collaborative ecosystem in genomic research and diagnostics. Illumina's strong financial performance is reflected in its consistent revenue growth and expanding market share, making it a formidable player in the global healthcare landscape. As the demand for precision medicine rises and genomic data becomes increasingly integral to modern healthcare, Illumina is poised to capture significant market opportunities. With a focus on innovation, evolving technologies, and a long-term vision for enhancing human health through genomics, Illumina remains a compelling investment proposition in an era where genetic insights are paramount.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Illumina Inc's most recent financial statements, the company has Net Margin of -36.1%.
You don't have any saved screeners yet
